Atrium Therapeutics, Inc.
NASDAQ:RNABiotechnology
+$0.16 today
- Market cap
- $143.23M
- Beta
- 0.42
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$3.78
Volume 0.22M
Average 0.35M
RNA Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Atrium Therapeutics, Inc.NASDAQ: RNA
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income of -$16.63M in Q1 FY2026
Q1 FY2026 net income was -$16.63M.
Context
- Net income amounted to 265.9% of revenue in FY2025.
What to watch
Whether net income reaches the consensus estimate from 3 analysts of -$56.38M (+13.9%) for the fiscal year ending Dec 2026.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$16.63M-42.9% QoQ
- Last fiscal yearDec 2025
- -$49.5M— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | — | +13.9% | — |
| 3-year CAGR | — | +24.3% | — |
| 5-year CAGR | +8.5% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (49.5M) USD
- Year-over-year change
- —
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (49.5M) | — |
Net Income vs competitors
How RNA compares with its peers on the latest reported figures
No competitor Net Income figures are available to compare.
Cash Flow Statement
Atrium Therapeutics, Inc.
NASDAQ:RNA
Intrinsic Alpha fair value
Locked
Current Price
$6.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.